HEMO — Hemogenyx Pharmaceuticals Balance Sheet
0.000.00%
- £6.78m
- £7.88m
Annual balance sheet for Hemogenyx Pharmaceuticals, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.499 | 1.81 | 6.84 | 2.53 | 1.25 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.032 | 0.056 | 0.008 | 0.01 | 0.005 |
Prepaid Expenses | |||||
Total Current Assets | 0.554 | 1.92 | 7.14 | 2.59 | 2.17 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.233 | 0.269 | 0.797 | 3.92 | 3.31 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 1.05 | 2.66 | 8.52 | 7.09 | 6.11 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 0.182 | 1.78 | 0.353 | 0.748 | 0.652 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.4 | 1.77 | 0.329 | 3.82 | 3.29 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -0.347 | 0.891 | 8.19 | 3.28 | 2.82 |
Total Liabilities & Shareholders' Equity | 1.05 | 2.66 | 8.52 | 7.09 | 6.11 |
Total Common Shares Outstanding |